Merck and Moderna Report Positive Late-Stage Results for Personalized mRNA Cancer Vaccine
Merck and Moderna said their personalized messenger RNA cancer vaccine, used with Keytruda, met its primary goals in a late-stage trial of more than one thousand one hundred patients with advanced melanoma, significantly extending recurrence-free survival.